[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
March 2016

Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing

Author Affiliations
  • 1Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Washington, DC
  • 2Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland
JAMA Intern Med. 2016;176(3):399-402. doi:10.1001/jamainternmed.2015.7799

Prescription opioid abuse is a major public health problem in the United States.1 The opioid analgesic hydrocodone bitartrate, traditionally available in combination with nonopioid analgesics, is one of the most commonly abused opioids.2 In 2011, hydrocodone combination analgesic products were involved in almost 100 000 abuse-related emergency department visits in the United States, more than double the number in 2004.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×